Health Care · Pharmaceutical Preparations

PCRX Pacira BioSciences, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1396814137 filings
Russell 2000

PCRX at a glance

Pacira BioSciences, Inc. (PCRX, SEC CIK 1396814) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Pacira BioSciences, Inc. (PCRX) reported revenue of $726.4 million (up 3.6% from FY2024) and net income of $7.0 million. Diluted EPS was $0.16.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Pacira BioSciences, Inc. (PCRX) shares worth $636.3 million in 13F-HR filings.
  • In the last 90 days, PCRX insiders reported 0 open-market purchases ($0) and 1 open-market sale ($218K) on Form 4, a net sale of $218K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$726.4M
+3.6% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$218K
13F holders
28 funds
$636.3M · −1 vs prior quarter
Latest 8-K
Nov 17, 2026
Item 7.01 · Item 5.02 · Item 1.02 · Item 1.01 · Item 2.04 · Item 2.01 · Item 3.03 · Item 3.01 · Item 5.01 · Item 5.03

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Innovative non-opioid pain therapies including EXPAREL, ZILRETTA, and iovera° for postsurgical and osteoarthritis pain management
  • New strategic plan "5x30" launched in Jan 2025 targeting 3M+ patients, double-digit revenue CAGR, 5% gross margin improvement, 5 clinical programs, 5 partnerships by 2030
  • 2025 acquisition of GQ Bio Therapeutics expanding pipeline with gene therapy (PCRX-201) for osteoarthritis in Phase 2 development
  • Net sales growth: EXPAREL $575.1M (2025) up from $549.0M (2024), ZILRETTA steady ~$117M, iovera° sales increased to $24.2M in 2025
  • FDA approved label expansion for EXPAREL in Nov 2023 adding adductor canal and sciatic nerve blocks, broadening usage for over 3 million lower extremity procedures annually

Risk Factors

  • Ongoing patent litigation against WhiteOak and Qilu threatens exclusive rights to EXPAREL and ZILRETTA, risking loss of patent protection and regulatory exclusivity
  • Significant revenue concentration with EXPAREL at 79% and ZILRETTA at 16% of total 2025 revenue, exposing the company to commercial risks in these products
  • Dependence on third-party cold-chain distributors for EXPAREL risks product spoilage if temperature controls fail, with limited insurance coverage for losses
  • Intense competition from generic opioids and immediate-release steroids, including established generics for OA pain, may limit market share and pricing power
  • Commercial success depends on obtaining timely hospital formulary approvals and physician prescribing, with delays or restrictions potentially reducing revenues

Management Discussion & Analysis

  • Revenue $726.4M, up 4% YoY from $701.0M; EXPAREL $575.1M (+5%), ZILRETTA $116.6M (-1%), iovera° $24.2M (+6%)
  • Gross margin 79% in 2025 vs 76% in 2024; cost of goods sold declined 12% to $149.7M
  • Best segment: EXPAREL sales $575.1M (+5%), worst: ZILRETTA sales $116.6M (-1%)
  • Cash used for share repurchases: $50M for 2 million shares in Q4 2025; no dividend or capex specifics disclosed
  • 2026 outlook: Expanded Asian-Pacific access via LG Chem partnership with $2M upfront; tariff risks mitigated by recent US Supreme Court ruling; ongoing challenges from generic litigation and investment in R&D (44% increase)

AI summary of the PCRX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New acquisition risk: Viatris merger announced October 8, 2026, creating employee, customer, supplier and stock-price disruption
  • Most material update: Merger agreement restricts acquisitions, debt, equity issuance and capital expenditures without Viatris consent
  • Regulatory and legal risk: Hart-Scott-Rodino clearance and absence of governmental legal restraints required to complete the merger
  • Financial risk: $7.4 million merger costs incurred by September 30, 2026, with additional fees payable regardless of closing
  • Divestiture risk: Up to $70.0 million of iovera° milestone payments depend on Zimmer revenue targets through December 31, 2031

Management Discussion & Analysis

  • Q3 revenue $176.7M, down 2% YoY from $179.5M
  • Gross margin decreased two percentage points YoY, driven by higher ZILRETTA costs and inventory reserves
  • EXPAREL revenue $142.5M, up 2%; ZILRETTA revenue $29.8M, up 3%
  • Operating cash flow $133.2M through September, with $73.6M divestiture proceeds and $50.0M share repurchases
  • Outlook: cash resources sufficient for 12 months; tariff volatility expected to pressure gross margins

AI summary of the PCRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 17, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Merger closing triggers a Common Stock Change Event under the Notes
  • Holders notified of a Make-Whole Fundamental Change, potentially affecting conversion economics

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Merger completion removed nine directors and six officers from Pacira’s board and management
  • John Miraglia and Michael Rainerman assumed officer and director roles at the surviving corporation

Item 1.02: Termination of a Material Definitive Agreement

  • Merger completion triggered repayment of $96,392.50 outstanding under Pacira’s Credit Agreement
  • Credit Agreement and all lender commitments terminated on November 17, 2026

Item 1.01: Entry into a Material Definitive Agreement

  • $287.5 million of 2.125% convertible notes due 2029 remain outstanding
  • Merger converts noteholders’ equity conversion right into cash based on $36.50 per share and the applicable conversion rate

Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation

  • Item 2.04 contains no standalone event details
  • Investors should assess the referenced Items 1.01, 1.02 and 2.01 for any obligations or transaction terms affecting Pacira BioSciences

Item 2.01: Completion of Acquisition or Disposition of Assets

  • Viatris completed its acquisition of Pacira on November 17, 2026, making Pacira a wholly owned subsidiary
  • Cash consideration: $36.50 per share, with 32,929,780 shares tendered, representing approximately 66.46% ownership

Item 3.03: Material Modification to Rights of Security Holders

  • Rights modification linked to the transactions and governance changes disclosed in Items 1.01, 2.01, 3.01, 5.01 and 5.03
  • Investor impact depends on the referenced deal, listing, control and charter details elsewhere in the filing

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule

  • Merger consummated, triggering Nasdaq trading halt before market open on November 17, 2026
  • Form 25 delisting and Section 12(b) deregistration to remove Pacira shares from Nasdaq

Item 5.01: Changes in Control of Registrant

  • Viatris acquired 100% ownership of Pacira BioSciences upon merger completion on November 17, 2026
  • Pacira shareholders’ control ended, with the company becoming a wholly owned Viatris subsidiary

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Merger-triggered restatement of Pacira’s certificate of incorporation and bylaws effective at closing
  • New governing documents replace prior versions, potentially changing shareholder rights and corporate governance

Item EX-99.1: Item EX-99.1

  • Viatris transaction closed November 17, 2026, converting Pacira into a wholly owned subsidiary and ending common-stock ownership
  • Convertible notes now convert only into cash, based on $36.50 per share and the applicable conversion rate
Filed Nov 12, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Ninth Circuit reversal reinstates Pacira’s royalty obligation for EXPAREL manufactured using the 200-liter process
  • District Court must recalculate RDF’s pre-judgment interest owed on 45-liter EXPAREL royalties
Filed Nov 5, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Viatris’ tender offer values Pacira at $36.50 per share in cash, subject to withholding taxes and transaction conditions
  • Pacira expected to become Viatris’ wholly owned subsidiary following the merger

AI summaries of PCRX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PCRX

Don't miss the next PCRX filing

  • Alerts as it files. A push when PCRX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PCRX, by share count.
  • Ask anything. An AI agent that reads every PCRX filing and answers with sources.

PCRX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Froimson MarkUNov 17, 2026$36.50
Cross ShawnDNov 17, 2026-
Young AlethiaDNov 17, 2026-
Young AlethiaDNov 17, 2026-
Cross ShawnUNov 17, 2026$36.50
Cross ShawnDNov 17, 2026$36.50
Young AlethiaDNov 17, 2026$36.50
Young AlethiaDNov 17, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$701.0M$726.4M
Operating Income--$73.4M$19.2M
Net Income$42.0M-$99.6M$7.0M
Op. Margin--10.5%2.6%
Net Margin--14.2%1.0%
Balance Sheet
Total Assets$1.6B$1.6B$1.3B
Equity-$778.3M$693.1M
ROE--12.8%1.0%
Per Share
EPS$0.89$-2.15$0.16
Cash Flow
Operating CF-$189.4M$152.0M
CapEx$15.2M$10.6M$15.3M

Source: XBRL data in Pacira BioSciences, Inc. (PCRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PCRX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PCRX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$636.3M
Q2 202629$639.8M
Q1 202630$581.5M
Q4 202528$675.6M
Q3 202528$696.9M
Q2 202529$678.2M
Q1 202527$532.7M
Q4 202422$340.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 221 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PCRX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
8-KNov 17, 2026Analysis-
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
8-KNov 12, 2026Analysis-
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Nov 3, 2026--
4Oct 9, 2026--
8-KOct 8, 2026Analysis-
4Aug 18, 2026--
SC 13GAug 7, 2026-
10-QAug 4, 2026Analysis
8-KAug 4, 2026Analysis-

Related Health Care companies

All Health Care →

PCRX SEC filings: frequently asked questions

Are PCRX insiders buying or selling?

In the last 90 days, Pacira BioSciences, Inc. (PCRX) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $217,920 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold PCRX stock?

As of September 30, 2026, the largest Pacira BioSciences, Inc. (PCRX) holders among the 13F filers tracked by SignalX were BlackRock ($173.7 million), Vanguard Portfolio Management LLC ($59.4 million), Dimensional Fund Advisors ($56.9 million), State Street Corp ($53.7 million), D.E. Shaw & Co ($46.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PCRX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Pacira BioSciences, Inc. (PCRX) reported revenue of $726.4 million (up 3.6% from FY2024) and net income of $7.0 million. Diluted EPS was $0.16. The figures come from the XBRL data in the 10-K.

What are the main risks in PCRX's latest 10-K?

In the 10-K filed February 26, 2026, Pacira BioSciences, Inc. (PCRX) flagged: Ongoing patent litigation against WhiteOak and Qilu threatens exclusive rights to EXPAREL and ZILRETTA, risking loss of patent protection and regulatory exclusivity. Significant revenue concentration with EXPAREL at 79% and ZILRETTA at 16% of total 2025 revenue, exposing the company to commercial risks in these products. (AI summary of the Risk Factors section.)

What did PCRX report in its latest 8-K?

Pacira BioSciences, Inc. (PCRX) filed an 8-K on November 17, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 5.02 (Departure/Appointment of Directors or Principal Officers), Item 1.02 (Termination of a Material Definitive Agreement), Item 1.01 (Entry into a Material Definitive Agreement), Item 2.04 (Triggering Events That Accelerate or Increase a Direct Financial Obligation), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.03 (Material Modification to Rights of Security Holders), Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule), Item 5.01 (Changes in Control of Registrant) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Merger closing triggers a Common Stock Change Event under the Notes.

What are the latest PCRX SEC filings?

Pacira BioSciences, Inc. (PCRX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and a Form 4 insider filing on November 17, 2026.

What is PCRX's SEC CIK number?

Pacira BioSciences, Inc. (PCRX)'s SEC Central Index Key (CIK) is 1396814. EDGAR lists every PCRX filing under that number.

Ask anything about PCRX

The research agent reads PCRX's filings, financials, insider trades and 13F holders, then answers with sources.